---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-012566"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:23:12.366817+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BriaCell presents positive Bria-IMT data at AACR; 15/18 alive, immune activation in anergic patients

## Summary
- 15 of 18 patients enrolled since 2021 remain alive; survival compares favorably to 6.7-9.8 months in similar studies.
- PFS benefit: most patients had PFS similar or higher than prior therapy, suggesting better tolerability and clinical effectiveness.
- Immune activation in 70% of anergic patients (weak immune systems) and 89% of non-anergic after Bria-IMT combo.
- 8 of 17 HR+ patients (large segment) experienced PFS benefit; no immunotherapies shown to work in HR+ breast cancer.
- Next-gen Bria-OTS2.0 significantly more effective than Bria-OTS in activating naïve T-cells; planned for Phase I/IIa.

## SEC filing metadata
- accession: 0001493152-23-012566
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223012566/0001493152-23-012566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223012566/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-012566
- JSON: https://secwatch.observer/filing/0001493152-23-012566.json
- Plain text: https://secwatch.observer/filing/0001493152-23-012566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.